• Mashup Score: 1
    article - 7 month(s) ago

    IntroductionChronic lymphocytic leukemia (CLL) is the most common type of leukemia affecting adults in western countries, mainly affecting older adults, with a median age at diagnosis of 72 years;1,2 its incidence and prevalence are expected to further increase in the short-term, proportionally increasing with the aging of the population.Chemo-immunotherapy regimens (eg, fludarabine…

    Tweet Tweets with this article
    • Chemo-immunotherapy regimens have been the standard of care for #ChronicLymphocyticLeukemia. Yet, novel targeted agents—like #BTK and B-cell lymphoma-2 inhibitors—offer therapeutic options with higher #efficacy and personalized treatment. Learn more: https://t.co/BOKL4lNyrg #CLL https://t.co/2eC26XEqnd

  • Mashup Score: 0

    Sparing lymph nodes until after immunotherapy treatment may result in improved antitumor immune response among patients with cancer, according to a study published in Cell. “This study helps clarify how immunotherapies work and where the reservoir of cells is that is responding to the therapies, so we can think about developing better immunotherapies that harness those cells in the lymph

    Tweet Tweets with this article
    • Leaving lymph nodes intact could increase efficacy of cancer immunotherapy. https://t.co/f3HD5gylX8 #efficacy #cancer #HemOnc #OncAlert #MedEd @parkerici @UCSF

  • Mashup Score: 0

    Several lines of evidence have shown that rituximab (RTX)-treated patients are at high risk of severe coronavirus disease 2019 (COVID-19).1 Thus, health authorities have considered patients receiving RTX as extremely high priority for anti-SARS-CoV-2 vaccination. However, a major issue relates to the high risk of reduced vaccination efficacy in these patients.2 Indeed, a metaanalysis conducted in…

    Tweet Tweets with this article
    • Editorial Importance of SARS-CoV-2 Spike Antibodies and B Cell Reconstitution to Optimize the Prevention Strategy of COVID-19 📰 https://t.co/BNz35shChQ #coronavirus #vaccination #efficacy #rituximab https://t.co/jVntlF2byt